ClinicalTrials.gg
Active, not recruitingNCT06375759Updated Nov 10, 2026

Mis S-S Bypass Versus Adhesion Lysis in PTS

An interventional study of A novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass and Intradural Adhesion Lysis in Syringomyelia and Spinal Cord Injury, sponsored by Xuanwu Hospital, Beijing. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment

How we know

Updated Nov 10, 2026Now Active, not recruitingResults publication added+10 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Spinal Cord Injuries with a site in China — 26 open to participants now, 32 under way, none of them phase 3. Spinal Cord Injuries · China.

Enrollment
16th of 71
80 · median 36
Started
2025
with 12 others
No phase
44 of 80
22 open now
Primary completion
2027-06
later than 20 of 31 live
Registered
47th of 80
by date
Lead sponsor
6 of 80
Xuanwu Hospital, Beijing

Among the 80 studies in Spinal Cord Injuries with a site in China, this one is the 16th largest by enrollment of the 71 interventional ones that give a count, is one of 13 that started in 2025, is one of 44 with no phase, reaches primary completion later than 20 of the 31 other live ones, and was the 47th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

26 of the 80 studies in Spinal Cord Injuries with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Spinal Cord Injuries with a site in China, or all of them as a file.
02

Study summary

To determine whether A novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass results in better patient outcomes with improved quality of life and fewer complications compared to intradural adhesion lysis in individuals with posttraumatic Syringomyelia.

Read the detailed description

Recently, our team was the first to report in the Journal of Neurosurgery: Spine (JNSSPINE) a minimally invasive subarachnoid-subarachnoid cerebrospinal fluid bypass technique for the treatment of post-traumatic syringomyelia. This novel approach has attracted considerable international attention and achieved favorable clinical outcomes for the treatment of post-traumatic syringomyelia. To establish high-level evidence, participants with posttraumatic Syringomyelia will be randomized to either have A novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass or intradural adhesion Lysis. The participant will then return to the neurosurgeon's office at the following time points which are consistent with standard of care practice: 3-6, 12±2months. At these visits, the clinician will complete a physical exam and the participant will report on the prognosis of symptoms and complete questionnaires. A spine MRI will be performed 3-6, 12±2months after the surgery.

The multicenter design, target sample size, assessor masking, eligibility criteria, and outcome hierarchy described in this record were specified in the ethics-approved protocol before enrollment of the first participant. The initial public registry entry did not fully reflect the finalized protocol. The registry record was corrected on 2026-11, before database lock and before any unblinded between-group analysis, to align it with the prospectively approved protocol.

03

Conditions studied

  • Syringomyelia
  • Spinal Cord Injury

Keywords

  • syringomyelia
  • spinal cord injury
  • posttraumatic syringomyelia
  • bypass
04

Who can participate

The criteria were revised on the registry on Nov 10, 2026. See what changed

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of traumatic spinal cord injury
  • Evidence of progressive neurological deficit and/or pain syndrome
  • MRI showing a syringomyelia due to spinal cord injury
  • Both myelography and MRI show extensive arachnopathy exceeding 2 spinal segments in length

Exclusion criteria

Exclusion Criteria:

  • Chiari malformation
  • Myelomalacia
  • Subarachnoid cyst
  • Syringomyelia due to other spinal diseases (such as degenerative spinal disease)
  • Marked spinal kyphosis
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    A novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass

    After dissections of the normal arachnoid mater at the cephalic and caudal sites, 2 tubes made of medical grade silicone (internal diameter 1.1 mm, external diameter 2.5 mm; Sophysa Systems Corp.) were inserted into the cephalic and caudal ends of the normal subarachnoid space. The tubes were only inserted into the normal subarachnoid space, with the remaining portions running subcutaneously.

    Procedure: A novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass

  • Active comparator
    Intradural Adhesion Lysis

    The dura is opened sharply, exposing the spinal cord. After microsurgical dissection adhesion, the dura is sewn closed with a dural graft.

    Procedure: Intradural Adhesion Lysis

Interventions

  • ProcedureA novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass

    After dissections of the normal dura mater at the cranial and caudal sites, a tunneling device (a passer) was used to create a subcutaneous tunnel. Two tubes made of medical grade silicone (internal diameter 1.1 mm, external diameter 2.5 mm; Sophysa Systems Corp.) were inserted into the cranial and caudal ends of the normal subarachnoid space. Under the surgical microscope, the normal dura was incised bilaterally approximately 3 mm on either side of the midline at the cranial end. The arachnoid was opened, with the proximal ends of the drainage tubes inserted approximately 5 cm into the normal subarachnoid space, with the remaining portions running subcutaneously. No loosening operations were performed at the site of injury. The incisions were sutured layer by layer

  • ProcedureIntradural Adhesion Lysis

    Intradural spinal cord Adhesion Lysis

06

What researchers measure

Primary outcomes

  1. The Number of Patients With Clinical Improvement

    Number of patients who experienced improvement in clinical or neurological symptoms-such as; sensory dysfunction (numbness, paresthesia, or sensory loss), neuropathic pain, motor weakness, gait impairment, bowel and bladder dysfunction, and spasticity.

    Time frame: 3-6, 12±2 months

Secondary outcomes

  1. change of the volume of syrinx,

    defined as change in length, maximal cross-sectional diameter, or both.

    Time frame: 3-6, 12±2 months

  2. Klekamp and Sammi syringomyelia scale

    for evaluating the spinal cord function, Each item is scored on a scale from 0 to 5, with 5 representing the best possible functional status.

    Time frame: 3-6, 12±2 months

  3. modified Japanese Orthopaedic Association Scores (mJOA)

    Motor function, sensory, bladder function;for evaluating the spinal cord function;0-17, higher scores mean a better outcome

    Time frame: 3-6, 12±2 months

  4. xuanwu syringomyelia scale

    for evaluating the spinal cord function, for evaluating the spinal cord function;0-18, higher scores mean a worse outcome

    Time frame: 3-6, 12±2 months

  5. complication

    various complication, such as fever, csf fistula

    Time frame: 3-6, 12±2 months

  6. ASIA score

    American Spinal Injury Association(ASIA) Score for evaluating the spinal cord function, degree of the spinal cord function, motor1-100, sensory 1-224, higher scores mean a better outcome

    Time frame: 3-6, 12±2 months

  7. VAS score

    VAS Score for evaluating the degree of the pain, VAS 0-10, higher scores mean a worse outcome

    Time frame: 3-6, 12±2 months

07

Study locations

1 site
08

References and documents

Publications

  • Zhang C, Yuan C, Wang J, Wu H, Chen Z, Jian F, Guan J. A novel Minimally-Invasive technique for Non-Traumatic postoperative adhesive Syringomyelia. Eur Spine J. 2026 Apr;35(4):2095-2104. doi: 10.1007/s00586-025-09197-x. Epub 2025 Aug 11. PubMed 40788489 ↗
  • Hayashi T, Ueta T, Kubo M, Maeda T, Shiba K. Subarachnoid-subarachnoid bypass: a new surgical technique for posttraumatic syringomyelia. J Neurosurg Spine. 2013 Apr;18(4):382-7. doi: 10.3171/2013.1.SPINE12828. Epub 2013 Feb 22. PubMed 23432327 ↗
  • Yuan C, Xia P, Duan W, Wang J, Guan J, Du Y, Zhang C, Liu Z, Wang K, Wang Z, Wang X, Wu H, Chen Z, Jian F. Long-Term Impairment of the Blood-Spinal Cord Barrier in Patients With Post-Traumatic Syringomyelia and its Effect on Prognosis. Spine (Phila Pa 1976). 2024 Mar 15;49(6):E62-E71. doi: 10.1097/BRS.0000000000004884. Epub 2023 Nov 28. PubMed 38014747 ↗
  • Heiss JD. Cerebrospinal Fluid Hydrodynamics in Chiari I Malformation and Syringomyelia: Modeling Pathophysiology. Neurosurg Clin N Am. 2023 Jan;34(1):81-90. doi: 10.1016/j.nec.2022.08.007. Epub 2022 Nov 3. PubMed 36424067 ↗
  • Hemley SJ, Bilston LE, Cheng S, Stoodley MA. Aquaporin-4 expression and blood-spinal cord barrier permeability in canalicular syringomyelia. J Neurosurg Spine. 2012 Dec;17(6):602-12. doi: 10.3171/2012.9.SPINE1265. Epub 2012 Oct 19. PubMed 23082850 ↗
  • Guan J, Yuan C, Yao Q, Du Y, Fang Z, Zhang L, Jia S, Zhang C, Liu Z, Wang K, Duan W, Wang Z, Wang X, Wu H, Chen Z, Jian F. A novel scoring system for assessing adult syringomyelia associated with CM I treatment outcomes. Acta Neurol Belg. 2023 Jun;123(3):807-814. doi: 10.1007/s13760-023-02264-4. Epub 2023 Apr 12. PubMed 37046133 ↗
  • Guan J, Yuan C, Zhang C, Ma L, Yao Q, Cheng L, Liu Z, Wang K, Duan W, Wang X, Wu H, Chen Z, Jian F. Intradural Pathology Causing Cerebrospinal Fluid Obstruction in Syringomyelia and Effectiveness of Foramen Magnum and Foramen of Magendie Dredging Treatment. World Neurosurg. 2020 Dec;144:e178-e188. doi: 10.1016/j.wneu.2020.08.068. Epub 2020 Aug 15. PubMed 32805463 ↗
  • Yuan C, Zhang C, Wang J, Wu H, Chen Z, Jian F, Guan J. A novel minimally invasive surgical technique for posttraumatic syringomyelia: subarachnoid-subarachnoid bypass. J Neurosurg Spine. 2025 Feb 21;42(5):641-649. doi: 10.3171/2024.10.SPINE24987. Print 2025 May 1. PubMed 39983113 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 24 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Apr 2024 → Jun 2025, primary completion Apr 2025 → Jun 2027 and completion Apr 2027 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2024
First posted
Apr 19, 2024
StartActual
Jun 25, 2025was Apr 2024
Primary completionEst.
Jun 25, 2027was Apr 2025
CompletionEst.
Jun 25, 2027was Apr 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 10, 2026
Sites
1 site added, 1 site removed
Show site
  • Fengzeng Jian · Beijing, China
Show 1 removed
  • Fengzeng Jian · Beijing, China
Nov 10, 2026
Start date
Apr 2024→Jun 25, 2025 (actual)
Nov 10, 2026
Primary completion
Apr 2025→Jun 25, 2027
Nov 10, 2026
Study completion
Apr 2027→Jun 25, 2027
Nov 10, 2026
Enrollment
200 (estimated)→80 (actual)
Nov 10, 2026
Eligibility
4 inclusion criteria added, 1 removed; 1 exclusion criterion edited, 4 added
What changed in the criteria
Inclusion criteria
  • Removed1) history of traumatic spinal cord injury or other infection; 2) evidence of progressive neurological deficit, and/or pain syndrome; 3) MRI showing a syringomyelia due to spinal trauma or other infection; and 4) minimum follow-up period of more than 1 year.
  • AddedHistory of traumatic spinal cord injury
  • AddedEvidence of progressive neurological deficit and/or pain syndrome
  • AddedMRI showing a syringomyelia due to spinal cord injury
  • AddedBoth myelography and MRI show extensive arachnopathy exceeding 2 spinal segments in length
Exclusion criteria
  • AddedChiari malformation
  • AddedMyelomalacia
  • AddedSubarachnoid cyst
  • EditedChiari-malformation, myelomalacia, subarachnoid cyst, syringomyeliaSyringomyelia due to other spinal diseases (such as degenerative spinal disease)
  • AddedMarked spinal kyphosis
Nov 10, 2026
Interventions
Changed Subarachnoid-Subarachnoid (S-S) Bypass→A novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass. Arm changed Subarachnoid-Subarachnoid (S-S) Bypass→A novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass
Nov 10, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore complicationNow The Number of Patients With Clinical ImprovementTime frame: 12 months → 3-6, 12±2 months
Nov 10, 2026
Publications
Results publication added: Yuan C, Zhang C, Wang J, Wu H, Chen Z, Jian F, Guan J. A novel minimally invasive surgical technique for posttraumatic syringomyelia: subarachnoid-subarachnoid… PubMed 39983113 ↗
Nov 10, 2026
Secondary outcomes
1 edited, 4 time frame changed, 2 added, 1 description edited
What changed in the outcomes
  • Editedimprovement or resolutionchange of the volume of syrinx,Time frame: 3-6, 12 and 24 months → 3-6, 12±2 months
  • AddedcomplicationTime frame: 3-6, 12±2 months
  • AddedVAS scoreTime frame: 3-6, 12±2 months
  • Time frameASIA score3-6, 12 and 24 months → 3-6, 12±2 months
  • Time frameKlekamp and Sammi syringomyelia scale3-6, 12 and 24 months → 3-6, 12±2 months
  • Time framemodified Japanese Orthopaedic Association Scores (mJOA)3-6, 12 and 24 months → 3-6, 12±2 months
  • Time framexuanwu syringomyelia scale3-6, 12 and 24 months → 3-6, 12±2 months
  • DescriptionKlekamp and Sammi syringomyelia scale: how it is measured was reworded
Nov 10, 2026
Title
Subarachnoid-Subarachnoid (Mis S-S) Bypass Versus Adhesion Lysis in Spinal Arachnoiditis and SyringomyeliaPTS
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Active, not recruiting
    Publications Results publication added: Yuan C, Zhang C, Wang J, Wu H, Chen Z, Jian F, Guan J. A novel minimally invasive surgical technique for posttraumatic syringomyelia: subarachnoid-subarachnoid… PubMed 39983113 ↗
    1 site added, 1 site removed
    Show site
    • Fengzeng Jian · Beijing, China
    Show 1 removed
    • Fengzeng Jian · Beijing, China
    Start date Apr 2024→Jun 25, 2025 (now actual)
    Primary completion Apr 2025→Jun 25, 2027
    Study completion Apr 2027→Jun 25, 2027
    Enrollment 200 (estimated)→80 (actual)
    Eligibility 4 inclusion criteria added, 1 removed; 1 exclusion criterion edited, 4 added
    What changed in the criteria
    Inclusion criteria
    • Removed1) history of traumatic spinal cord injury or other infection; 2) evidence of progressive neurological deficit, and/or pain syndrome; 3) MRI showing a syringomyelia due to spinal trauma or other infection; and 4) minimum follow-up period of more than 1 year.
    • AddedHistory of traumatic spinal cord injury
    • AddedEvidence of progressive neurological deficit and/or pain syndrome
    • AddedMRI showing a syringomyelia due to spinal cord injury
    • AddedBoth myelography and MRI show extensive arachnopathy exceeding 2 spinal segments in length
    Exclusion criteria
    • AddedChiari malformation
    • AddedMyelomalacia
    • AddedSubarachnoid cyst
    • EditedChiari-malformation, myelomalacia, subarachnoid cyst, syringomyeliaSyringomyelia due to other spinal diseases (such as degenerative spinal disease)
    • AddedMarked spinal kyphosis
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore complicationNow The Number of Patients With Clinical ImprovementTime frame: 12 months → 3-6, 12±2 months
    Secondary outcomes 1 edited, 4 time frame changed, 2 added, 1 description edited
    What changed in the outcomes
    • Editedimprovement or resolutionchange of the volume of syrinx,Time frame: 3-6, 12 and 24 months → 3-6, 12±2 months
    • AddedcomplicationTime frame: 3-6, 12±2 months
    • AddedVAS scoreTime frame: 3-6, 12±2 months
    • Time frameASIA score3-6, 12 and 24 months → 3-6, 12±2 months
    • Time frameKlekamp and Sammi syringomyelia scale3-6, 12 and 24 months → 3-6, 12±2 months
    • Time framemodified Japanese Orthopaedic Association Scores (mJOA)3-6, 12 and 24 months → 3-6, 12±2 months
    • Time framexuanwu syringomyelia scale3-6, 12 and 24 months → 3-6, 12±2 months
    • DescriptionKlekamp and Sammi syringomyelia scale: how it is measured was reworded
    Interventions Changed Subarachnoid-Subarachnoid (S-S) Bypass→A novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass. Arm changed Subarachnoid-Subarachnoid (S-S) Bypass→A novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass
    Title Subarachnoid-Subarachnoid (Mis S-S) Bypass Versus Adhesion Lysis in Spinal Arachnoiditis and SyringomyeliaPTS
    + 9 other changes: verification date, responsible party, oversight details, description, conditions, design details, contact details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06375759
Collaborators
The First Hospital of Hebei Medical University, Jinan Central Hospital
Responsible party
Sponsor
First posted
Apr 19, 2024
Start date
Jun 25, 2025
Primary completion
Jun 25, 2027 (estimated)
Completion
Jun 25, 2027 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion